HK1159123A1 - Novel polypeptide for resisting tumors caused by eb (epstein-barr) viruses, and application and preparation method thereof - Google Patents

Novel polypeptide for resisting tumors caused by eb (epstein-barr) viruses, and application and preparation method thereof

Info

Publication number
HK1159123A1
HK1159123A1 HK11113462.9A HK11113462A HK1159123A1 HK 1159123 A1 HK1159123 A1 HK 1159123A1 HK 11113462 A HK11113462 A HK 11113462A HK 1159123 A1 HK1159123 A1 HK 1159123A1
Authority
HK
Hong Kong
Prior art keywords
barr
epstein
viruses
preparation
application
Prior art date
Application number
HK11113462.9A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1159123A1 publication Critical patent/HK1159123A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11113462.9A 2009-12-17 2011-12-14 Novel polypeptide for resisting tumors caused by eb (epstein-barr) viruses, and application and preparation method thereof HK1159123A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009102428380A CN102101888B (zh) 2009-12-17 2009-12-17 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法

Publications (1)

Publication Number Publication Date
HK1159123A1 true HK1159123A1 (en) 2012-07-27

Family

ID=44154977

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11113462.9A HK1159123A1 (en) 2009-12-17 2011-12-14 Novel polypeptide for resisting tumors caused by eb (epstein-barr) viruses, and application and preparation method thereof

Country Status (30)

Country Link
US (1) US8883161B2 (xx)
EP (1) EP2514768B1 (xx)
JP (1) JP5683603B2 (xx)
KR (1) KR101464842B1 (xx)
CN (1) CN102101888B (xx)
AP (1) AP3535A (xx)
AU (1) AU2010333588B2 (xx)
BR (1) BR112012017350A2 (xx)
CA (1) CA2784784C (xx)
CL (1) CL2012001609A1 (xx)
CO (1) CO6541633A2 (xx)
CR (1) CR20120329A (xx)
CU (1) CU20120096A7 (xx)
DK (1) DK2514768T3 (xx)
DO (1) DOP2012000164A (xx)
EA (1) EA030638B1 (xx)
ES (1) ES2634944T3 (xx)
GE (1) GEP20156228B (xx)
HK (1) HK1159123A1 (xx)
HU (1) HUE033298T2 (xx)
IL (1) IL220296A (xx)
MA (1) MA33921B1 (xx)
MX (1) MX2012006952A (xx)
NZ (1) NZ600729A (xx)
PE (1) PE20121722A1 (xx)
SG (1) SG181553A1 (xx)
TN (1) TN2012000253A1 (xx)
UA (1) UA104933C2 (xx)
WO (1) WO2011072501A1 (xx)
ZA (1) ZA201205217B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
US10071358B2 (en) * 2011-12-08 2018-09-11 Protein Design Lab, Ltd. Antibiotic preparation method and platform system based on same
WO2016023491A1 (en) * 2014-08-12 2016-02-18 The University Of Hong Kong Biophosphonate compounds and gamma delta t cell-mediated therapy for treating epstein-barr virus-associated disorders
CN104604799B (zh) * 2015-02-05 2017-11-21 南华大学 一种鉴定eb病毒对淋巴瘤的诱发性的方法
US20210373004A1 (en) * 2018-11-19 2021-12-02 Bioaster Methods and reagents for multiplex binding experiments
CN111333724B (zh) * 2018-12-19 2022-03-15 中国人民解放军军事科学院军事医学研究院 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用
CN111848817B (zh) * 2020-07-28 2021-11-09 中国农业大学 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用
CN112125959B (zh) * 2020-10-10 2022-07-29 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用
CN113880914B (zh) * 2021-04-25 2023-11-21 内蒙古农业大学 一种抗肿瘤多肽及其衍生物
CN114369158B (zh) * 2021-09-28 2024-04-19 北京亦科信息菌素研究院有限公司 一种抗新冠病毒的信息菌素及其应用
CN113999304B (zh) * 2021-10-13 2023-10-24 北京市农林科学院 抗肠菌素单克隆抗体mAb4及其在肠菌素检测中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164612C (zh) 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
CN1314806C (zh) 2005-01-14 2007-05-09 四川大学 小型化抗eb病毒肿瘤多肽及其应用与制备方法
CN1274829C (zh) 2004-12-10 2006-09-13 四川大学华西医院 抗eb病毒所致肿瘤多肽及其应用与制备方法
WO2007083175A1 (en) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
CN101643501B (zh) * 2008-11-07 2012-06-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗生素及其核苷酸序列、制备方法与应用
CN101633699B (zh) * 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用

Also Published As

Publication number Publication date
CN102101888A (zh) 2011-06-22
AP2012006327A0 (en) 2012-06-30
BR112012017350A2 (pt) 2018-07-24
ZA201205217B (en) 2013-03-27
CO6541633A2 (es) 2012-10-16
MX2012006952A (es) 2012-10-03
IL220296A (en) 2017-07-31
JP5683603B2 (ja) 2015-03-11
HUE033298T2 (en) 2017-11-28
AP3535A (en) 2016-01-13
EP2514768B1 (en) 2017-04-05
UA104933C2 (uk) 2014-03-25
MA33921B1 (fr) 2013-01-02
AU2010333588B2 (en) 2013-05-02
NZ600729A (en) 2014-12-24
CL2012001609A1 (es) 2012-12-07
CN102101888B (zh) 2013-03-20
DK2514768T3 (en) 2017-07-17
EP2514768A1 (en) 2012-10-24
KR20120117826A (ko) 2012-10-24
EA030638B1 (ru) 2018-09-28
DOP2012000164A (es) 2012-12-31
US20130066051A1 (en) 2013-03-14
TN2012000253A1 (en) 2013-12-12
CA2784784C (en) 2017-10-03
CU23931B1 (xx) 2013-06-28
EA201270655A1 (ru) 2012-12-28
GEP20156228B (en) 2015-01-26
US8883161B2 (en) 2014-11-11
SG181553A1 (en) 2012-07-30
EP2514768A4 (en) 2013-12-04
JP2013514060A (ja) 2013-04-25
AU2010333588A1 (en) 2012-06-21
CR20120329A (es) 2012-10-23
IL220296A0 (en) 2012-07-31
WO2011072501A1 (zh) 2011-06-23
CU20120096A7 (es) 2012-07-31
CA2784784A1 (en) 2011-06-23
PE20121722A1 (es) 2012-12-15
KR101464842B1 (ko) 2014-11-27
ES2634944T3 (es) 2017-09-29

Similar Documents

Publication Publication Date Title
HK1159123A1 (en) Novel polypeptide for resisting tumors caused by eb (epstein-barr) viruses, and application and preparation method thereof
EP2518126A4 (en) Composition for heat-storage material, and heat-storage material
EP2623545A4 (en) CELLULOSE SPUTTERING METHOD, CELLULOSE NANOFIBERS, MASTER MIXTURE, AND RESIN COMPOSITION
GB201006753D0 (en) Process for preparing an immunolobulin composition
EP2612909A4 (en) METHOD FOR PRODUCING VIRUS VECTORS
GB0822068D0 (en) Methods for virus design
ZA201206956B (en) Excipients for stabilising viral particle, polypeptides or biological material
IL216935A0 (en) Process for the preparation of nacre mechano-structured by mechanosynthesis, mechano-structured nacre thus obtained and uses thereof
EP2294226A4 (en) METHOD FOR DETECTING VIRUSES
EP2600761A4 (en) MEMBRANE COMPOSITION FOR BIOSENSOR, BIOSENSOR AND METHODS OF MAKING THE SAME
AP3508A (en) Mannich-base inhibitor for decalcification, preparation method and application thereof
EP2439198A4 (en) NOVEL PROCESS FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING ROSUVASTATIN, AND CORRESPONDING PREPARATION METHOD
GB201103931D0 (en) Printable composition, method and uses thereof
HK1181056A1 (en) Atelocollagen separation method, method for preparing modified atelocollagen, and atelocollagen-and collagen-based matrix prepared by the methods
EP2594281A4 (en) INSULIN LIPID COMPLEX, MANUFACTURING METHOD AND PREPARATION THEREFROM
ZA201304161B (en) Process for preparing chromium(iii) oxide
ZA201600550B (en) Compositions, methods and uses for inducing viral growth
EP2634183B8 (en) Method for preparing 1,3,5-trioxane
ZA201103543B (en) Novel method for preparing granulates of active principles, and granulates obtained thereof
PL2588488T3 (pl) Kompleks sukcynylokazeiny z żelazem (III) i sposób jego wytwarzania
EP2634182B8 (en) Method for preparing 1,3,5-trioxane
PL2350108T3 (pl) C-glikozydy i sposoby wytwarzania c-glikozydów
IL220941A0 (en) Method for producing recombinant virus
EP2650082A4 (en) Ceramic composite for photoconversion, and method for manufacture thereof
HK1179519A1 (zh) 免疫原、組合物及其用途和製備方法

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191215